Arcus Biosciences Inc Cash Flow-to-Debt Ratio
Arcus Biosciences Inc cash flow-to-debt ratio. Arcus Biosciences Inc (RCUS) has a Cash Flow-to-Debt Ratio of -0.29x as of March 2026, meaning its operating cash flow of $-138.00 Million could theoretically repay 0% of its total liabilities ($473.00 Million) in one year. Check Arcus Biosciences Inc earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Arcus Biosciences Inc (2016–2025)
Cash flow-to-debt ratio of Arcus Biosciences Inc from 2016 to 2025. Historical debt coverage capacity for Arcus Biosciences Inc across 10 annual periods. Check how aggressively does Arcus Biosciences Inc reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
Arcus Biosciences Inc Cash Flow-to-Debt Ratio by Year (2016–2025)
Arcus Biosciences Inc cash flow-to-debt ratio by year from 2016 to 2025. Year-by-year debt coverage analysis for Arcus Biosciences Inc. For the full cash flow conversion analysis, see Arcus Biosciences Inc (RCUS) cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.95x | $-482.00 Million | $508.00 Million | ▼ -271.2% |
| 2024 | -0.26x | $-170.00 Million | $665.00 Million | ▲ +47.1% |
| 2023 | -0.48x | $-306.00 Million | $633.00 Million | ▼ -175.9% |
| 2022 | 0.64x | $438.00 Million | $688.00 Million | ▲ +286.5% |
| 2021 | -0.34x | $-256.17 Million | $750.45 Million | ▼ -182.9% |
| 2020 | 0.41x | $111.17 Million | $269.99 Million | ▲ +122.0% |
| 2019 | -1.87x | $-73.46 Million | $39.27 Million | ▼ -74.0% |
| 2018 | -1.08x | $-43.00 Million | $39.98 Million | ▼ -57.1% |
| 2017 | -0.68x | $-25.06 Million | $36.62 Million | ▲ +45.9% |
| 2016 | -1.26x | $-12.94 Million | $10.24 Million | — |